BrightPath Biotherapeutics
About:
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies.
Website: https://www.brightpathbio.com/
Top Investors: Nippon Venture Capital, Fast Track Initiative, Inc., DBJ Capital, KSP, MBLVC
Description:
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.
Total Funding Amount:
1.2B JPY
Estimated Revenue Range:
$10M to $50M
Headquarters Location:
Tokyo, Tokyo, Japan
Founded Date:
2003-05-08
Founders:
Ito Kyogo
Number of Employees:
11-50
Last Funding Date:
2014-08-29
IPO Status:
Public
Industries:
© 2025 bioDAO.ai